A Louisiana jury this week awarded a staggering $9 billion in punitive damages to the companies behind Actos (Pioglitazone HCl). Takeda Pharmaceutical and its partner from 1999–2006, Eli Lilly, have promised to appeal the decision, which came after the jury decided in favor of plaintiff Terrence Allen of Attica, N.Y., who blamed Actos for causing his bladder cancer after taking the drug for five years. The jury’s decision came in part after hearing that Takeda lost or destroyed documents compiled by 46 current and former employees and sales representatives involved in marketing Actos.

Poll Question:
How confident are you that Takeda and Lilly will see the punitive damages reduced substantially on appeal?

A great deal


Not at all

Previous articleA $1,000 Proteome? Protein Sequencers Raise the Question
Next articleGSK Taking Aim at Cancer in MD Anderson’s Moon Shots Program